Carmell Therapeutics Corporation
NASDAQ Capital MarketTotal Valuation
Carmell Therapeutics Corporation carries a market capitalization of 5.94M, placing it among publicly traded companies globally. Its enterprise value stands at 6.49M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 5.94M |
| Enterprise Value | 6.49M |
Share Statistics
Carmell Therapeutics Corporation currently has 28.97M shares outstanding.
| Shares Outstanding | 28.97M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 119.36, and the price-to-book ratio stands at -0.09.
| PE Ratio | N/A |
| PS Ratio | 119.36 |
| PB Ratio | -0.09 |
| P/TBV Ratio | -1.27 |
| P/FCF Ratio | -1.37 |
| P/OCF Ratio | -1.37 |
Enterprise Valuation
| EV / Sales | 128.93 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Carmell Therapeutics Corporation maintains a current ratio of 0.16, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -13.56, indicating conservative leverage, while an interest coverage ratio of -97.95 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.16 |
| Quick Ratio | 0.08 |
| Debt / Equity | -13.56 |
| Debt / EBITDA | -0.13 |
| Interest Coverage | -97.95 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -31.70 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.12 |
Taxes
| Income Tax | -97,279.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Carmell Therapeutics Corporation's stock has declined approximately -92.69259% over the past 52 weeks. The 50-day moving average sits at 0.35, while the 200-day moving average is 0.63.
| Beta (5Y) | N/A |
| 52-Week Price Change | -92.69259% |
| 50-Day Moving Average | 0.35 |
| 200-Day Moving Average | 0.63 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Carmell Therapeutics Corporation generated 50,318.00 in revenue and converted that into -10.37M in net income, yielding earnings per share of -0.49. EBITDA reached -4.80M, while operating income came in at -5.00M.
| Revenue | 50,318.00 |
| Gross Profit | 43,961.00 |
| Operating Income | -5.00M |
| Pretax Income | -10.75M |
| Net Income | -10.37M |
| EBITDA | -4.80M |
| EBIT | -5.00M |
| Earnings Per Share (EPS) | -0.49 |
Balance Sheet
Carmell Therapeutics Corporation holds 157,139.00 in cash and equivalents against 638,993.00 in total debt, resulting in a net debt position of 84,019.00. Total book value stands at -68.87M, with working capital of -4.92M providing operational flexibility.
| Cash & Cash Equivalents | 157,139.00 |
| Total Debt | 638,993.00 |
| Net Debt | 84,019.00 |
| Equity (Book Value) | -68.87M |
| Book Value Per Share | -3.20 |
| Working Capital | -4.92M |
Cash Flow
Carmell Therapeutics Corporation produced -4.39M in operating cash flow over the past twelve months.
| Operating Cash Flow | -4.39M |
| Capital Expenditures | N/A |
| Free Cash Flow | -4.39M |
| FCF Per Share | -0.20 |
Margins
Carmell Therapeutics Corporation operates with a gross margin of 87.37, reflecting its pricing power and cost economics. The operating margin of -9,933.82 and net profit margin of -20,605.47 provide insight into operational efficiency.
| Gross Margin | 87.37 |
| Operating Margin | -9,933.82 |
| Pretax Margin | -21,359.64 |
| Profit Margin | -20,605.47 |
| EBITDA Margin | -9,541.79 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -39.67 |
| FCF Yield | -73.08 |
Scores
Carmell Therapeutics Corporation posts an Altman Z-Score of -81.08, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -81.08 |